Array BioPharma received Breakthrough Therapy Designation from the FDA for encorafenib (Braftovi), in combination with binimetinib (Mektovi) and cetuximab for the treatment of patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC) as detected by an FDA-approved test, after failure of one to two prior lines of therapy for metastatic disease. BRAFV600E-mutant mCRC patients have a mortality risk more…